csii + sitagliptin

**CSII + sitagliptin** refers to the combination therapy of *continuous subcutaneous insulin infusion (CSII)*—typically delivered via insulin pump—with the oral DPP-4 inhibitor sitagliptin. This combination is used primarily in patients with newly diagnosed type 2 diabetes mellitus (T2DM). CSII provides a continuous basal supply of insulin and allows for bolus dosing with meals, while sitagliptin increases incretin levels by inhibiting the enzyme dipeptidyl-peptidase-4 (DPP-4), resulting in increased insulin release and decreased glucagon levels in a glucose-dependent manner. Studies show that combining CSII with sitagliptin improves glycemic control, reduces glycemic variability, and enhances β-cell function compared to CSII alone, with additional benefits of reduced hypoglycemia and lower insulin requirements[1][4][5][6][7].

Other names

csii + sitagliptincsii plus sitagliptincontinuous subcutaneous insulin infusion + sitagliptincontinuous subcutaneous insulin infusion plus sitagliptin